The history of vaccination against cytomegalovirus

Medical Microbiology and Immunology

Volumn 204, Issue 3, 2015, Pages 247-254

  Plotkin, Stanley ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Towne strain; Vaccination; Vaccine trials

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PLASMID; PRIORITY JOURNAL; RECIPIENT; REVIEW; STEM CELL; VACCINATION; VIREMIA; VIRUS RECOMBINANT; VIRUS REPLICATION; CYTOMEGALOVIRUS INFECTIONS; HISTORY; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; VACCINATION;

EID: 84929963166     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-015-0388-z     Document Type: Review

References (70)

1. Ho M (2008) The history of cytomegalovirus and its diseases. Med Microbiol Immunol 197(2):65–73
2. Reddehase MJ, Koszinowski UH (1984) Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369–371
3. Stagno S, Pass RF, Cloud G et al (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256(14):1904–1908
4. Dollard SC, Grosse SD, Ross DS (2007) New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17(5):355–363
5. Limaye AP, Bakthavatsalam R, Kim HW et al (2006) Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81(12):1645–1652
6. Ljungman P, Hakki M, Boeckh M (2010) Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24(2):319–337
7. Osawa R, Singh N (2009) Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care 13(3):R68
8. Koch S, Larbi A, Ozcelik D et al (2007) Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 1114:23–35
9. Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1(7845):1–5
10. Plotkin SA, Furukawa T, Zygraich N, Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12(3):521–527
11. Neff BJ, Weibel RE, Buynak EB, McLean AA, Hilleman MR (1979) Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 160(1):32–37
12. Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23(Suppl. 3):90–96
13. Stratton KR, Durch JS, Lawrence RS (2001) Vaccines for the 21st century. A tool for decisionmaking. Committee to study priorities for vaccine development. Division of health promotion and disease prevention, Institute of Medicine, The National Academies, Washington
14. Plotkin SA, Huygelen C (1976) Cytomegalovirus vaccine prepared in WI-38. Dev Biol Stand 37:301–305
15. Plotkin SA, Farquhar J, Hornberger E (1976) Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 134(5):470–475
16. Just M, Buergin-Wolff A, Emoedi G, Hernandez R (1975) Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection 3(2):111–114
17. Fleisher GR, Starr SE, Friedman HM, Plotkin SA (1982) Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 136(4):294–296
18. Quinnan GVJ, Delery M, Rook AH et al (1984) Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101(4):478–483
19. Adler SP, Hempfling S, Starr S et al (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Ped Infect Dis J 17:200–206
20. Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA (1981) Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 143(4):585–589
21. Carney WP, Hirsch MS, Iacoviello VR, Starr SE, Fleisher G, Plotkin SA (1983) T-lymphocyte subsets and proliferative responses following immunization with cytomegalovirus vaccine. J Infect Dis 147(5):958
22. Jacobson MA, Sinclair E, Bredt B et al (2006) Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 35(3):332–337
23. Friedman AD, Furukawa T, Plotkin SA (1982) Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates. J Infect Dis 146(2):255–259
24. Friedman AD, Michelson S, Plotkin SA (1982) Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine. Infect Immun 38(3):1068–1072
25. Cha TA, Edward T, Kemble W, Duke GM, Mocarski E, Spaete R (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70(1):78–83
26. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW (2001) A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 11(3):191–200
27. Plotkin SA, Huang ES (1985) Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 152(2):395–397
28. Plotkin SA, Weibel RE, Alpert G et al (1985) Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J Infect Dis 151(4):737–739
29. Plotkin SA, Higgins R, Kurtz JB et al (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:1176–1178
30. Adler SP, Starr SE, Plotkin SA et al (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171(1):26–32
31. Heineman TC, Schleiss M, Bernstein DI et al (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193(10):1350–1360
32. Gonczol E, Hudecz F, Ianacone J, Dietzschold B, Starr S, Plotkin SA (1986) Immune responses to isolated human cytomegalovirus envelope proteins. J Virol 58:661–664
33. Gonczol E, Ianacone J, Ho W (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers. Vaccine 8:130–136
34. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64(3):1079–1085
35. Frey SE, Harrison C, Pass RF et al (1999) Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 180(5):1700–1703
36. Pass RF, Duliege AM, Boppana S et al (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180(4):970–975
37. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP (2002) Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21(2):133–138
38. Pass RF, Zhang C, Evans A et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360(12):1191–1199
39. Sabbaj S, Pass RF, Goepfert PA, Pichon S (2011) Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 203(11):1534–1541
40. Pass R (2010) Slide presentation by Robert Pass at ICAAC meeting in 2010 Update on CMV Vaccines
41. Bernstein DI, Munoz FM, Callahan ST et al (2014) Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine. Pediatric Academic Societies Meeting, Abstract
42. Griffiths PD, Stanton A, McCarrell E et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377(9773):1256–1263
43. Walter EA, Greenberg PD, Gilbert MJ et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333(16):1038–1044
44. Gyulai Z, Endresz V, Burian K et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181(5):1537–1546
45. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101(7):2686–2692
46. Malouli D, Hansen SG, Nakayasu ES et al (2014) Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest 124(5):1928–1944
47. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90(5):1751–1767
48. Wloch MK, Smith LR, Boutsaboualoy S et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197(12):1634–1642
49. Kharfan-Dabaja MA, Boeckh M, Wilck MB et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12(4):290–299
50. Smith LR, Wloch MK, Chaplin JA et al (2013) Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. Vaccines 1:398–414
51. Shedlock DJ, Talbott KT, Wu SJ et al (2012) Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother 8(11):1668–1681
52. Loomis RJ, Lilja AE, Monroe J et al (2013) Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31(6):919–926
53. Lilja AE, Mason PW (2012) The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30(49):6980–6990
54. Bernstein DI, Reap EA, Katen K et al (2009) Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28(2):484–493
55. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102(50):18153–18158
56. Wang D, Li F, Freed DC et al (2011) Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29(48):9075–9080
57. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G (2011) Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 52(2):113–118
58. Lilleri D, Kabanova A, Revello MG et al (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8(3):e59863
59. Hahn G, Revello MG, Patrone M et al (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78(18):10023–10033
60. Wen Y, Monroe J, Linton C et al (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32(30):3796–3804
61. Fu TM, Wang D, Freed DC et al (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30(52):7469–7474
62. Fu TM, An Z, Wang D (2014) Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32(22):2525–2533
63. Geall AJ, Verma A, Otten GR et al (2012) Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 109(36):14604–14609
64. Becke S, Aue S, Thomas D et al (2010) Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant. Vaccine 28(38):6191–6198
65. Cayatte C, Schneider-Ohrum K, Wang Z et al (2013) Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. J Virol 87(20):11107–11120
66. La RC, Longmate J, Lacey SF et al (2012) Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205(8):1294–1304
67. Kirchmeier M, Fluckiger AC, Soare C et al (2014) Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol 21(2):174–180
68. Macagno A, Bernasconi NL, Vanzetta F et al (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84(2):1005–1013
69. Barkai G, Ari-Even RD, Barzilai A et al (2014) Universal neonatal cytomegalovirus screening using saliva—report of clinical experience. J Clin Virol 60(4):361–366
70. Lanzieri TM, Bialek SR, Ortega-Sanchez IR, Gambhir M (2014) Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine 32(30):3780–3786